Arteriosclerosis
Not recruitingStudy on Inclisiran for Preventing Heart Disease in High-Risk Patients
- Disease:Arteriosclerosis
- Substances:Inclisiran
Spain- Participants:18–64 years · 65+ years
- Substances:Inclisiran
- Sponsor:Novartis Pharma AG
Rare diseases
Investigational molecules
Locations
Back to Spain2 clinical trials in Lebrija Sevilla, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)
Spain
SpainThe busiest research cities in the country
What the registry says about research in the country
Clinical trials focusing on stroke prevention and heart conditions are evaluating innovative therapeutic approaches for patients with atrial fibrillation. These studies aim to assess new treatment options that could offer improved safety profiles while maintaining effectiveness in preventing strokes.
Research emphasizes comparative effectiveness of new anticoagulation therapies.
Groundbreaking research in atherosclerotic cardiovascular disease prevention is underway, examining novel treatments for high-risk patients. These studies evaluate interventions aimed at reducing major adverse cardiovascular events.
Studies focus on innovative approaches to prevent cardiovascular complications in at-risk populations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.